Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Episurf Medical AB (publ)    EPIS B   SE0003491562

EPISURF MEDICAL AB (PUBL)

(EPIS B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Episurf Medical : Episealer® publication available online

10/08/2020 | 01:31pm EST

Episurf Medical (Nasdaq: EPIS B) today communicates that the publication with the title "Patient specific metal implants for focal chondral and osteochondral lesions in the knee - Excellent clinical results at 2 years" from a European multicentre study with 24 months' follow-up of 80 Episealer® Knee implant patients, which is accepted for publication in the scientific journal Knee Surgery, Sports Traumatology, Arthroscopy (KSSTA), is now available online. Link to the publication: https://rdcu.be/b8fin

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

https://news.cision.com/episurf/r/episealer--publication-available-online,c3213149

https://mb.cision.com/Main/14691/3213149/1316851.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

All news about EPISURF MEDICAL AB (PUBL)
11/27EPISURF MEDICAL : enters into international advisory agreement
AQ
11/26EPISURF MEDICAL : carries out a directed share issue and raises proceeds of SEK ..
AQ
11/13EPISURF MEDICAL : First Episealer® surgery in Scotland performed
AQ
11/04EPISURF MEDICAL : First Episealer® Talus surgery in Scandinavia performed
AQ
10/26DNB MARKETS - EPISURF MEDICAL :  Clinical data strengthens the case
AQ
10/26EPISURF MEDICAL : First Episealer® surgery performed in Asia
AQ
10/23EPISURF MEDICAL : Interim Report 1 July - 30 September 2020
AQ
10/15EPISURF MEDICAL : enters into a distribution agreement for additional markets in..
AQ
10/14EPISURF MEDICAL : Members of the Nomination Committee for Episurf Medical's Annu..
AQ
10/08EPISURF MEDICAL : Episealer® publication available online
AQ
More news
Financials
Sales 2020 6,00 M 0,71 M 0,71 M
Net income 2020 -72,8 M -8,57 M -8,57 M
Net cash 2020 81,0 M 9,54 M 9,54 M
P/E ratio 2020 -5,54x
Yield 2020 -
Capitalization 409 M 48,1 M 48,1 M
EV / Sales 2020 54,7x
EV / Sales 2021 34,3x
Nbr of Employees 25
Free-Float 89,1%
Chart EPISURF MEDICAL AB (PUBL)
Duration : Period :
Episurf Medical AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EPISURF MEDICAL AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 4,00 SEK
Last Close Price 2,21 SEK
Spread / Highest target 81,0%
Spread / Average Target 81,0%
Spread / Lowest Target 81,0%
EPS Revisions
Managers
NameTitle
Pål Ryfors Chief Executive Officer
Dennis D. Stripe Chairman
Katarina Flodstrom Chief Operating & Regulatory Officer
Veronica Wallin Chief Financial Officer
Leif Erik Sigfrid Ryd Independent Director
Sector and Competitors